Fludrocortisone acetate trials for Prostate cancer

All Fludrocortisone acetate trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Fludrocortisone acetate for Prostate cancer

• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 330 locations
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 288 locations
• Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
  NCT06353386 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 77 locations

Common questions

How many trials study Fludrocortisone acetate for Prostate cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.